Mentored Patient-Oriented Research Career Development Award

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT00203684
Recruitment Status : Recruiting
First Posted : September 20, 2005
Last Update Posted : February 17, 2017
Information provided by:
University of California, Los Angeles

Brief Summary:

Asthmatics have inflammation in the large airways (tubes through which air travels in and out of the lungs). The large airways are located in the central lung. New research shows that asthmatics also have inflammation in the small airways. The small airways are located in the peripheral lung (the parts of the lung away from the central lung).

Until now, most of the inhaled medications available have been made up of big particles that never reach the peripheral lung. The purpose of this study is to try to measure the level of inflammation in the peripheral lung in asthmatics and see if this inflammation can be decreased with different types of inhaled corticosteroids. The investigators will check airway inflammation before and after use of an inhaled corticosteroid that has a large particle size and should only reach the large airways (Flunisolide-CFC), and before and after use of an inhaled, small particle corticosteroid that should reach both the large and small airways (Flunisolide-HFA).

Subjects will make 6 study visits over two phases of the study. In the first phase, the investigators will collect baseline information about subjects while they are using placebo (inactive substance). In the second phase, subjects will take either the large or small particle corticosteroid.

Visits will involve questionnaires and various tests measuring lung function (such as spirometry, forced oscillation, and methacholine challenge). Exhaled nitric oxide will be measured as an indication of inflammation. Subjects will also measure and make note of lung function at home twice daily using a peak expiratory flow meter. Two of the visits will involve fiberoptic bronchoscopy so that the investigators may collect cells and tissue samples without surgery. Another two of the visits will involve the use of high resolution computed tomography (HRCT) scans to indirectly evaluate disease in distant parts of the lungs.

Condition or disease Intervention/treatment Phase
Asthma Distal Lung Inflammation Drug: Flunisolide-HFA Phase 1 Phase 2

Study Type : Interventional  (Clinical Trial)
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Diagnostic
Official Title: The Effects of Different Sized Inhaled Corticosteroids on Peripheral Lung Inflammation in Asthma Assessed Through Lung Tissue Samples (SMART Protocol)

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Asthma
Drug Information available for: Flunisolide
U.S. FDA Resources

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 50 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Aged 18 to 50 years. Younger subjects are excluded due to greater concerns with respect to risks from radiation and bronchoscopy in children; older subjects due to greater risks of bronchoscopy.
  • Mild to moderate persistent asthma (forced expiratory volume in 1 second [FEV1] greater than or equal to 70% predicted {Hankinson, 1999 #266}; PC20 less than or equal to 8 mg/ml) and currently using only short acting inhaled beta agonists as needed for control of asthma symptoms.

Exclusion Criteria:

  • The use of the following medications will exclude subjects from entering the study:

    • Oral or parenteral steroids within 6 months
    • Inhaled corticosteroids within 3 months
    • Antileukotrienes, b-adrenergic blocking agents, inhaled cromolyn sodium or nedocromil, macrolide antibiotics, or investigational drugs within 1 month
    • Drugs or exposures which, in the opinion of the investigators, could influence study results
  • Tobacco within 1 year or less than or equal to 5 pack years.
  • Pregnant women, lactating women, or women of childbearing age not willing to take precautions to avoid becoming pregnant during the study.
  • Subjects with upper respiratory infection or receiving an influenza vaccine within 6 weeks of the study.
  • Subjects with a history of allergy or adverse reaction to inhaled beta agonists or methacholine.
  • Subjects with clinically significant evidence of cardiovascular, central nervous system, endocrine, gastrointestinal, hematopoietic, hepatic, psychiatric, or respiratory (other than asthma) disease

Eligibility will be determined by an investigator using the above inclusion/exclusion criteria.

No subjects will be excluded based on race or gender. Subjects must be between 18 and 50 in order to avoid greater risks of bronchoscopy and, in those under 18, exposure to radiation. To avoid risks, women will not be enrolled if pregnant, lactating or of childbearing potential and unwilling to undertake appropriate precautions.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00203684

Contact: Michelle Zeidler, MD 310-825-3806

United States, California
UCLA Asthma and Cough Center Recruiting
Los Angeles, California, United States, 90095
Contact: Michelle Ziedler, MD    310-825-3806      
Principal Investigator: Michelle Ziedler, MD         
Sponsors and Collaborators
University of California, Los Angeles
Principal Investigator: Michelle Zeidler, MD University of California, Los Angeles Identifier: NCT00203684     History of Changes
Other Study ID Numbers: 5K23RR018538-03 ( U.S. NIH Grant/Contract )
NIH grant #5K23RR018538-03
First Posted: September 20, 2005    Key Record Dates
Last Update Posted: February 17, 2017
Last Verified: February 2017

Additional relevant MeSH terms:
Bronchial Diseases
Respiratory Tract Diseases
Lung Diseases, Obstructive
Lung Diseases
Respiratory Hypersensitivity
Hypersensitivity, Immediate
Immune System Diseases
Pathologic Processes
Respiratory Tract Infections
Anti-Inflammatory Agents
Anti-Asthmatic Agents
Respiratory System Agents